Hemostasis Versus Immunosuppression in Preventing Postlaminectomy Epidural Fibrosis: An Experimental Study in Rats

Area of Science:

• Spinal Surgery
• Regenerative Medicine
• Pharmacology

Background:

• Epidural fibrosis (EF) is a common complication after spinal surgery, leading to scar tissue formation.
• Current strategies to mitigate EF have limitations.
• Tranexamic acid (TXA) and infliximab (INF) are investigated for their potential anti-fibrotic effects.

Purpose of the Study:

• To compare the efficacy of tranexamic acid (TXA) and infliximab (INF) in reducing epidural fibrosis (EF) following laminectomy in a rat model.
• To evaluate TXA's hemostatic and INF's immunosuppressive properties in preventing postoperative spinal fibrosis.

Main Methods:

• A rat laminectomy model (L1-L3) was used with three groups: control, TXA-treated, and INF-treated (n=7 per group).
• Topical application of TXA (10-20 mg/mL) and INF (1 mg/mL) was performed post-laminectomy.
• Histopathological analysis (H&E, Masson-Goldner's Trichrome) assessed EF severity, fibroblast density, inflammation, and neovascularization at eight weeks.

Main Results:

• TXA treatment resulted in significantly lower epidural fibrosis scores compared to both INF and control groups (p<0.05).
• TXA effectively reduced fibroblast proliferation, inflammatory cell infiltration, and collagen deposition.
• INF showed moderate anti-fibrotic effects but was less potent than TXA; no systemic side effects were observed for either treatment.

Conclusions:

• Topical tranexamic acid (TXA) is a more effective strategy than infliximab (INF) for preventing epidural fibrosis after laminectomy.
• TXA-induced hemostasis demonstrates superior anti-fibrotic capabilities compared to INF-induced immunosuppression in this model.
• These findings suggest TXA as a promising therapeutic agent to minimize postoperative fibrosis in spinal surgery.